ADC Therapeutics SA: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

AI Briefing

• – LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end
• – First quarter 2026 net product revenue of $20.0 million
• – Cash and cash equivalent balance as of March 31, 2026 was $105.8 million